NVAX is trading 5.5% up now at $9.98, extending a multi-day rally from the high-$8 range to mid-$9s. The move follows the company’s Q1 2026 earnings beat and improving sentiment around its COVID-19 vaccine franchise, with shares continuing to climb alongside a generally supportive broader market backdrop.